Stock Events

Stock Events

ObsEva SA. 

0
0
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Financials

-157.54%Profit Margin
Unprofitable
2017
2018
2019
2020
2021
2022
18.3MRevenue
-28.84MNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap208.49B
Amgen Inc. competes in the biopharmaceutical sector focusing on treatments in areas that may overlap with ObsEva's reproductive health products.
Merck
MRK
Mkt Cap362.35B
Merck & Co., Inc. offers a broad range of health solutions including women's health, directly competing with ObsEva's portfolio.
Pfizer
PFE
Mkt Cap157.65B
Pfizer Inc. has a diverse range of pharmaceutical products, including those in women's health, making it a competitor.
Novo Nordisk
NVO
Mkt Cap191.03B
Novo Nordisk A/S focuses on hormone replacement therapies and other treatments that can compete with ObsEva's reproductive health products.
Bristol-Myers Squibb
BMY
Mkt Cap128.81B
Bristol-Myers Squibb Company operates in various therapeutic areas, including those that could compete with ObsEva's focus areas.
Abbvie
ABBV
Mkt Cap466.45B
AbbVie Inc. has a strong presence in women's health through its hormonal therapies, competing with ObsEva.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap45.46B
Teva Pharmaceutical Industries Limited offers generic and specialty medicines, including in women's health, posing competition to ObsEva.
Lilly(Eli) &
LLY
Mkt Cap1.03T
Eli Lilly and Company has a portfolio that includes treatments for conditions in women's health, competing with ObsEva.
GSK
GSK
Mkt Cap100.62B
GlaxoSmithKline plc engages in the creation of pharmaceuticals, including those for women's health, making it a competitor.
Sanofi
SNY
Mkt Cap101.79B
Sanofi offers a broad range of healthcare solutions, including in areas that compete with ObsEva's focus on reproductive health.

About

ObsEva SA, a biopharmaceutical company, focuses on the development of novel therapies to improve women's reproductive health. It develops Nolasiban, an oral oxytocin receptor agonist for improving clinical pregnancy and live birth rates in women undergoing in-vitro fertilization. The company was founded in 2012 and is headquartered in Geneva, Switzerland.
Show more...
CEO
Employees
15
Country
Switzerland
ISIN
CH0346177709
WKN
000A3EELW

Listings

STU
DE
22D.STU
OTC Link
US
OBSEF

0 Comments

Share your thoughts

FAQ

What is ObsEva SA. stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange ObsEva SA. stocks are traded under the ticker 22D.STU.
What is ObsEva SA. revenue for the last year?▼
ObsEva SA. revenue for the last year amounts to 18.3M EUR.
What is ObsEva SA. net income for the last year?▼
22D.STU net income for the last year is -28.84M EUR.
How many employees does ObsEva SA. have?▼
As of September 27, 2026, the company has 15 employees.
In which sector is ObsEva SA. located?▼
ObsEva SA. operates in the Other sector.
When did ObsEva SA. complete a stock split?▼
ObsEva SA. has not had any recent stock splits.